BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Rhea-AI Summary

BillionToOne (Nasdaq: BLLN) has appointed renowned oncology physician-scientist Ethan Dmitrovsky, MD as Chief Medical Officer, Oncology, effective July 20, 2026. He will lead medical strategy for the Northstar liquid biopsy portfolio, focusing on expanding clinical adoption in solid-tumor treatment decisions and driving the company’s entry into minimal residual disease (MRD) testing.

According to BillionToOne, Dmitrovsky brings leadership experience from Frederick National Laboratory, MD Anderson Cancer Center, and Dartmouth, along with a track record of translating cancer research into FDA-approved therapies. The Northstar portfolio includes Northstar Select and Northstar Response plus recent launches Northstar PGx and Northstar Select CH.

Positive

• Appointment of CMO, Oncology brings high-profile oncology leader to guide Northstar strategy
• Northstar Select shown in a clinical study to detect 50%+ more clinically actionable alterations
• Northstar Response positioned as only tissue-free response monitoring test with single-molecule precision
• Expansion into MRD as a new strategic area for the Northstar platform
• Recent launches of Northstar PGx and Northstar Select CH add to assay portfolio depth

Negative

• None.

Market reaction after oncology leadership change: BLLN -3.97% in the Jul 20 session

-3.97%

7 alerts

-3.97% Session close to close

+6.9% Peak in 29 hr 40 min

$5.99B Market Cap

0.8x Rel. Volume

In the Jul 20 session, BLLN declined 3.97%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.9% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

BLLN's prior Northstar Response data event, news_id 1075858, recorded a 1.89% 24-hour reaction, prov...

Analysis

BLLN's prior Northstar Response data event, news_id 1075858, recorded a 1.89% 24-hour reaction, providing a company-specific reference. The appointment expands medical leadership, while Net Selling remains a sourced risk factor.

Key Figures

Leadership experience: more than two decades Flagship assays: two assays Actionable alterations: 50%+ more +1 more

4 metrics

Leadership experience more than two decades Dr. Dmitrovsky's cancer research and care career

Flagship assays two assays Northstar portfolio

Actionable alterations 50%+ more Northstar Select versus other commercially available liquid biopsies

Null reports half Northstar Select versus other commercially available liquid biopsies

Historical Context

5 past events · Latest: Jul 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	Earnings date notice	Neutral	+4.0%	Company scheduled second-quarter 2026 results and conference call for August 5.
Jun 29	Clinical data	Positive	+1.9%	Northstar Response outperformed imaging in predicting immunotherapy outcomes across 142 patients.
May 27	Conference participation	Neutral	+7.5%	Management announced participation in the William Blair Growth Stock Conference.
May 06	Quarterly earnings	Positive	+14.1%	First-quarter revenue reached $108.4M and 2026 revenue guidance increased.
May 01	Product launch	Positive	-6.9%	Unity Confirm launched with 16/16 concordance in internal validation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BLLN's prior news reactions were mixed: two positive events aligned with gains, while three neutral or positive events diverged from the headline direction.

Key Terms

liquid biopsy, minimal residual disease, single-molecule precision, all-trans-retinoic acid-based differentiation therapy

4 terms

liquid biopsy medical

"Northstar liquid biopsy portfolio as it enters its next phase of growth"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

minimal residual disease medical

"leading the company's entry into the minimal residual disease (MRD) space"

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

single-molecule precision technical

"Northstar Response is the only tissue-free response monitoring test with single-molecule precision"

Ability of a test, instrument, or technique to detect, measure, or manipulate individual molecules rather than averaging signals from large groups. Like hearing a single violin in an orchestra, it reveals tiny signals that bulk methods miss. For investors, single-molecule precision signals potential for greater diagnostic sensitivity, earlier detection, lower sample needs, and more targeted development, which can affect product differentiation, regulatory paths, and commercial value.

all-trans-retinoic acid-based differentiation therapy medical

"including establishing curative all-trans-retinoic acid-based differentiation therapy"

A therapy that uses all‑trans‑retinoic acid (ATRA), a vitamin A derivative, to force certain immature cancer cells to stop dividing and mature into non‑cancerous cells. Think of it like giving instructions that make unruly young cells 'grow up' and behave normally rather than trying to kill them outright. It matters to investors because successful differentiation therapy can change clinical trial outcomes, regulatory decisions, revenue prospects, and valuations for companies developing or selling the treatment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions

MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dr. Dmitrovsky will lead medical strategy for BillionToOne's Northstar liquid biopsy portfolio as it enters its next phase of growth, expanding its clinical adoption in guiding treatment decisions for patients with solid tumors and leading the company's entry into the minimal residual disease (MRD) space.

Dr. Dmitrovsky has shaped cancer research and care at some of the country's most respected institutions for more than two decades. He joins BillionToOne from the Frederick National Laboratory for Cancer Research, where he served as Laboratory Director and President of Leidos Biomedical Research. He previously served as Provost and Executive Vice President at the University of Texas MD Anderson Cancer Center and as Professor and Chair of Pharmacology and Toxicology at Dartmouth's Geisel School of Medicine. He graduated magna cum laude in Biochemical Sciences from Harvard University and received his medical degree from Cornell University Medical College, completing a residency in Internal Medicine at New York Hospital, Memorial Sloan Kettering Cancer Center, and an oncology fellowship at the National Cancer Institute. His work has repeatedly moved from the bench to the clinic, including establishing curative all-trans-retinoic acid-based differentiation therapy for acute promyelocytic leukemia, work reported in the New England Journal of Medicine that led to the therapy's FDA approval. He was recognized with selection as an American Cancer Society Professor and election as a fellow of the American Association for the Advancement of Science.

"My career has always centered on closing the gap between scientific discovery and patient care," said Dr. Dmitrovsky. "BillionToOne's Northstar platform represents exactly that kind of opportunity, giving oncologists tools that are sensitive and precise enough to inform real treatment decisions. I am excited to join the team at this stage and continue to build the clinical and scientific foundation that will support oncologists and their patients for years to come."

"Ethan is one of the most accomplished physician leaders in oncology today," said Oguzhan Atay, PhD, co-founder and CEO of BillionToOne. "His record of building large-scale clinical and research programs and taking discoveries from the lab to the clinic makes him exactly the kind of leader we need as we scale Northstar."

Northstar's portfolio includes two flagship assays. Northstar Select is the most sensitive therapy selection liquid biopsy for advanced solid tumors, proven in a head-to-head clinical study to uncover 50%+ more clinically actionable alterations than other commercially available liquid biopsies while cutting null reports in half. Northstar Response is the only tissue-free response monitoring test with single-molecule precision, enabling physicians to quantify tumor burden and monitor treatment response with a simple blood draw. Dr. Dmitrovsky's appointment builds on recent momentum for the platform, including the launches of Northstar PGx and Northstar Select CH.

About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates (QCT) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single molecule level. For more information, visit www.billiontoone.com.

Disclaimer
Northstar Select and Northstar Response may produce false-positive or false-negative results. Test results are not a guarantee of the presence or absence of disease or treatment response and should not be used as the sole basis for medical decision-making. Results should be interpreted in conjunction with the patient's clinical presentation, radiographic findings, and other diagnostic information. Northstar Response is intended to complement, not replace, standard clinical and radiographic assessment of disease status. Northstar Select and Northstar Response are laboratory-developed tests (LDTs) performed in a CLIA-certified and CAP-accredited laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the growth of the Northstar platform. These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, the risk that the Northstar platform does not grow and those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's most recently filed Quarterly Report on Form 10-Q, its Annual Report on Form 10-K, and other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.

Media Contact
billiontoone@moxiegrouppr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoone-appoints-ethan-dmitrovsky-md-as-chief-medical-officer-oncology-to-lead-medical-strategy-for-northstar-302828703.html

SOURCE BillionToOne

FAQ

What did BillionToOne (NASDAQ: BLLN) announce on July 20, 2026?

BillionToOne announced the appointment of Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology. According to BillionToOne, he will lead medical strategy for the Northstar liquid biopsy portfolio, supporting its growth in treatment decision-making and the company’s planned expansion into minimal residual disease (MRD) testing.

Who is Ethan Dmitrovsky, MD, and what is his role at BillionToOne (BLLN)?

Ethan Dmitrovsky, MD, is a physician-scientist and former Director of Frederick National Laboratory. According to BillionToOne, he becomes Chief Medical Officer, Oncology, responsible for medical strategy across the Northstar liquid biopsy portfolio, guiding clinical adoption in solid tumors and supporting the company’s move into MRD testing.

What is BillionToOne’s Northstar liquid biopsy portfolio for BLLN investors?

Northstar is BillionToOne’s liquid biopsy portfolio designed to guide cancer treatment decisions using blood-based tests. According to BillionToOne, it includes Northstar Select for therapy selection and Northstar Response for tissue-free response monitoring, plus newly launched assays Northstar PGx and Northstar Select CH, targeting broader oncology applications.

How does Northstar Select compare to other liquid biopsy tests in oncology?

Northstar Select is described as a highly sensitive therapy selection liquid biopsy for advanced solid tumors. According to BillionToOne, a head-to-head clinical study showed it identified over 50% more clinically actionable alterations than other commercial liquid biopsies while reducing null reports by approximately half for tested patients.

What is Northstar Response and how is it used in cancer care?

Northstar Response is a tissue-free response monitoring test with single-molecule precision for cancer patients. According to BillionToOne, it allows physicians to quantify tumor burden and monitor treatment response through a simple blood draw, supporting more informed, ongoing management of therapy effectiveness in clinical oncology practice.

How does Ethan Dmitrovsky’s appointment affect BillionToOne’s MRD strategy for BLLN?

His appointment is intended to support BillionToOne’s entry into minimal residual disease (MRD) testing with Northstar. According to BillionToOne, Dmitrovsky will help expand Northstar’s role beyond therapy selection and response monitoring into MRD applications, aiming to guide real-world treatment decisions for patients with solid tumors.

What recent product launches has BillionToOne reported within the Northstar platform?

BillionToOne reported recent launches of Northstar PGx and Northstar Select CH as additions to its oncology portfolio. According to BillionToOne, these assays build on momentum for Northstar, expanding its capabilities alongside Northstar Select for therapy selection and Northstar Response for treatment-response monitoring in solid tumors.